FDA-Approved Veterinary Ophthalmic Product for Chronic KCS & CSK in Dogs. Optimmune® (0.2% Cyclosporine, USP) from Merck Animal Health is the only FDA-approved ophthalmic used in dogs to treat dry eye, or chronic keratoconjunctivitis sicca (KCS) and inflammation of the cornea, or chronic superficial keratosis (CSK). Optimmune® works to increase natural tear production in the eye while also reducing inflammation and damage to the tear glands. It is clinically shown to increase natural tear production in KCS dogs1. Prolonged ocular contact time allows a lower dose concentration, and a therapeutic effect while avoiding systemic toxicity1. Sterile, preservative-free formulation reduces the chance of secondary infection and chemical irritation. Shelf life up to 24 months with no refrigeration. When applied as directed, each tube of Optimmune® can last 6-8 weeks. And it is available in 6 x 3.5 g tubes by prescription only. For full prescribing information, including directions for use, precautions and adverse reactions, see package insert. For ophthalmic use in dogs only. The safety of OPTIMMUNE® has not been determined in cases of preexisting viral or fungal ocular infections, nor in puppies, pregnant bitches, or dogs used for breeding. In clinical trials, ocular and periocular inflammatory reactions, transient hyperemia, epiphora, mild discomfort of the eye, and mild alopecia were reported in a small number of treated dogs. For full prescribing information, including directions for use, precautions and adverse reactions, see package insert. 1. US Patent # 4,839,342.